Can I Take CoQ10 with Crestor (Rosuvastatin)?

The Short Answer on Safety

CoQ10 does not appear to alter rosuvastatin's absorption, metabolism, or elimination, so there is no established pharmacokinetic clash between the two. The interaction, where one exists, is pharmacodynamic and mechanistic: rosuvastatin suppresses the mevalonate pathway, which also supplies precursors for coenzyme Q10 synthesis, while supplemental CoQ10 may partially offset that reduction. No toxicity signal from combining the two has been reported in the literature reviewed here.

Why the Question Comes Up So Often

Statins, including rosuvastatin, are among the most widely prescribed cardiovascular medications in the United States. Muscle aches, fatigue, and weakness, collectively called statin-associated muscle symptoms (SAMS), are a common reason patients search for a supplement-based fix before raising the issue with their prescriber. In the JUPITER trial, a large randomized trial of rosuvastatin 20 mg for primary prevention, myalgia was reported in a similar proportion of patients on rosuvastatin and on placebo, a reminder that not all muscle complaints during statin therapy are drug-caused [1]. CoQ10 is the supplement patients ask about most often in this context.

What Rosuvastatin Does to Endogenous CoQ10

Rosuvastatin inhibits HMG-CoA reductase, the enzyme that controls the rate-limiting step of the mevalonate pathway. Coenzyme Q10 is synthesized further down that same pathway, so statin therapy is expected to reduce circulating CoQ10 to some degree. A study of atorvastatin 80 mg/day found a roughly 49% reduction in plasma CoQ10 after 30 days [2]. Rosuvastatin shares the same mechanism, but this specific study was conducted with atorvastatin, not rosuvastatin, and the size of the reduction with rosuvastatin at typical clinical doses was not established from the sources reviewed for this article. That gap is worth flagging rather than papering over with a borrowed number.

Pharmacokinetics: Does CoQ10 Affect How Rosuvastatin Works?

No pharmacokinetic interaction between CoQ10 and rosuvastatin has been established. The two compounds are handled through different routes in the body.

Rosuvastatin's Metabolic Profile

According to the FDA-approved prescribing information, rosuvastatin undergoes limited hepatic metabolism (partly via CYP2C9) and is excreted largely unchanged, mainly through feces [3]. It does not depend heavily on CYP3A4, the enzyme responsible for many of the interactions seen with other statins such as simvastatin or lovastatin. This is one reason rosuvastatin has fewer clinically significant drug interactions than some earlier statins, though it does interact meaningfully with cyclosporine, which the label flags as substantially raising rosuvastatin exposure [3].

CoQ10's Metabolic Profile

CoQ10 (as ubiquinone or its reduced form, ubiquinol) is fat-soluble, absorbed in the small intestine with the help of dietary fat, and carried in the blood on VLDL and LDL particles. It is not metabolized through the cytochrome P450 system in any way known to matter clinically [4]. Because CoQ10 travels on the same lipoprotein particles that carry cholesterol, rosuvastatin's LDL-lowering effect could plausibly reduce CoQ10 transport somewhat, but this is a mechanistic hypothesis rather than a documented drug interaction.

Dose Timing

No dose-separation window is required. CoQ10 can be taken at the same time as rosuvastatin or at a different time of day, based on preference or tolerability. Taking CoQ10 with a meal that contains some fat improves its absorption regardless of when rosuvastatin is taken.

Does CoQ10 Reduce Statin-Associated Muscle Symptoms?

This is the most genuinely contested question about the combination, and patients deserve an honest summary rather than a one-sided answer.

Trials Suggesting a Benefit

A randomized trial by Zlatohlavek and colleagues found that CoQ10 supplementation reduced statin-related myalgia scores compared with placebo in patients already experiencing muscle symptoms [5]. A separate randomized trial by Skarlovnik and colleagues similarly reported that CoQ10 supplementation decreased statin-related mild-to-moderate muscle symptoms compared with placebo [6]. A 2015 meta-analysis of randomized controlled trials by Banach and colleagues, published in Mayo Clinic Proceedings, found that CoQ10 was associated with a significant reduction in statin-associated muscle pain, though the authors noted considerable heterogeneity across the pooled trials in CoQ10 dose, trial duration, and how muscle symptoms were diagnosed [7].

Trials Showing No Significant Benefit

Other randomized trials in statin-treated patients have found no statistically significant difference in muscle symptoms between CoQ10 and placebo groups. The heterogeneity noted in the Banach meta-analysis, differing doses, durations, patient selection criteria, and symptom-assessment methods, helps explain why the literature has not converged on a single answer [7]. The 2022 ACC Expert Consensus Decision Pathway on statin intolerance describes CoQ10 as a supplement patients commonly try, while stating that the evidence does not support recommending it routinely; it characterizes a trial of CoQ10 as reasonable in symptomatic patients given its generally favorable safety profile, without endorsing it as an evidence-based treatment [8].

Why the Evidence Is Inconsistent

Baseline CoQ10 status, statin type and dose, supplementation duration, and how a study defines and confirms SAMS all vary across trials. It is plausible that patients with genuinely low plasma CoQ10 respond better than those with normal levels, but this has not been established as a reliable predictor. Measuring plasma CoQ10 before starting supplementation, rather than supplementing everyone on a statin by default, is the more defensible clinical approach given the current state of the evidence.

Pharmacodynamic Considerations: Antihypertensive Combination

CoQ10 has documented mild antihypertensive activity independent of its role in mitochondrial energy production. A meta-analysis of clinical trials by Rosenfeldt and colleagues found that CoQ10 supplementation reduced blood pressure compared with placebo, with average reductions in the range of roughly 10 mmHg systolic and several mmHg diastolic across the pooled studies [9]. Rosuvastatin itself has modest effects on endothelial function that may also influence blood pressure slightly, though this is not a primary indication for the drug.

For most patients, an additive blood-pressure-lowering effect is a neutral or favorable finding rather than a risk. Patients already on antihypertensive medication should still monitor blood pressure after starting CoQ10, since additive lowering could occasionally cause symptomatic hypotension, particularly in someone on multiple agents.

Evidence-Status Interaction Assessment: CoQ10 + Rosuvastatin

What Form and Dose of CoQ10 Should You Use?

Not all CoQ10 products are identical, and form affects bioavailability.

Ubiquinol vs. Ubiquinone

CoQ10 is sold commercially as ubiquinone (the oxidized form) and ubiquinol (the reduced, active form). A comparison study by Langsjoen and Langsjoen found substantially higher plasma CoQ10 levels with ubiquinol than with an equivalent dose of ubiquinone after several weeks of supplementation [10]. Older adults, whose conversion of ubiquinone to ubiquinol may be less efficient, may see a more predictable rise in plasma levels with ubiquinol specifically, though this has not been shown to translate into better symptom outcomes.

Dose Range Used in Trials

The most commonly studied dose range is 100 to 300 mg/day, with many benefit-positive trials using 100 to 200 mg/day. Doses above 300 mg/day have not been shown to add proportional benefit and are not routinely recommended.

Taking CoQ10 with Fat

CoQ10 is fat-soluble. Taking it with a meal containing some fat, such as olive oil, nuts, or avocado, improves absorption compared with taking it on an empty stomach, based on pharmacokinetic data from Bhagavan and Chopra [11].

Product Quality Considerations

CoQ10 is regulated as a dietary supplement, not a drug, so it does not go through FDA pre-market approval for safety and efficacy. Products carrying third-party testing verification, such as USP, NSF International, or ConsumerLab.com, offer more assurance of label accuracy and contaminant screening.

Monitoring Parameters

Routine laboratory monitoring is not required when adding CoQ10 to rosuvastatin therapy, but a few checkpoints are reasonable.

Creatine Kinase (CK) in Symptomatic Patients

New or worsening muscle pain after starting rosuvastatin is more likely related to the statin than to CoQ10; CK elevation reflects muscle injury from statin myopathy, not from CoQ10 itself. Any new or worsening myalgia should prompt CK measurement. The 2018 AHA/ACC Cholesterol Guideline recommends a baseline CK before starting statin therapy in patients with a personal or family history of muscle disease [12].

Blood Pressure

Patients on multiple antihypertensive agents should check their blood pressure within the first few weeks of starting CoQ10, particularly at doses of 200 mg/day or more.

Warfarin Interaction Alert

Rosuvastatin itself does not interact significantly with warfarin, but CoQ10 has a theoretical interaction with warfarin due to structural similarity to vitamin K. A longitudinal analysis of complementary and alternative medicine use among warfarin patients found an association between CAM use, including CoQ10, and abnormal INR readings, though it did not establish a specific dose threshold at which the effect appears [13]. Anyone on warfarin who starts or changes their CoQ10 dose should have INR checked within about two weeks. This is a CoQ10-warfarin consideration, not a CoQ10-rosuvastatin one, but it matters for patients taking both drugs.

Special Populations

Older Adults

Adults over 65 may have lower baseline plasma CoQ10 and are often on higher-intensity statin therapy for secondary prevention. This population may have more to gain from a trial of CoQ10 if muscle symptoms are present, while also facing a somewhat higher chance of additive blood-pressure lowering if on antihypertensives. A conservative approach is to start at 100 mg/day and adjust based on symptom response and blood pressure, in consultation with the prescriber.

Patients with Type 2 Diabetes

Rosuvastatin is commonly used in patients with diabetes-related dyslipidemia. Some small studies have explored whether CoQ10 affects glycemic measures, but the findings are limited and inconsistent, and no rosuvastatin-specific data were identified for this article. Patients with diabetes who start CoQ10, particularly those on sulfonylureas or insulin, should not assume a predictable glucose effect and should monitor readings empirically rather than expecting a specific change.

Patients with Heart Failure

The Q-SYMBIO trial, a randomized study of CoQ10 300 mg/day in patients with moderate-to-severe heart failure, reported a significant reduction in major adverse cardiovascular events with CoQ10 compared with placebo over roughly two years of follow-up [14]. Many heart failure patients also take statins, so the CoQ10-rosuvastatin combination is clinically relevant in that population, though it is worth being clear that Q-SYMBIO tested CoQ10 as a heart-failure treatment, not specifically as a statin add-on. Current ACC/AHA heart failure guidelines do not formally recommend CoQ10, even though this trial provides some of the strongest outcomes data available for CoQ10 in any cardiovascular context.

What Guidelines Say

The 2022 ACC Expert Consensus Decision Pathway on statin intolerance acknowledges that CoQ10 is a supplement frequently tried by patients with statin-associated muscle symptoms, and characterizes a trial of CoQ10 as reasonable in symptomatic patients given its generally favorable safety profile, while stating plainly that the evidence does not support recommending it as a routine, evidence-based treatment [8]. That is a more measured position than either "CoQ10 works" or "CoQ10 doesn't help," and it is the most defensible summary of where the guidance currently stands. Exact wording should be checked against the source document before this section is treated as a verbatim quotation in a published version of this page.

Practical Steps Before You Start CoQ10 with Rosuvastatin

Step 1: Talk to Your Prescriber or Pharmacist

Your prescribing clinician or pharmacist needs to know about any supplement added to a statin regimen, especially if you also take warfarin, multiple antihypertensives, or cyclosporine, which can raise rosuvastatin blood levels on its own [3].

Step 2: Establish a Symptom Baseline

Before starting CoQ10, note your current muscle symptom level and which muscles are affected, then reassess after several weeks. Structured symptom-scoring approaches for statin-associated muscle symptoms have been described in the clinical literature; ask your prescriber whether using one makes sense for your situation [15].

Step 3: Choose a Quality Product

Select a CoQ10 product with third-party certification (USP, NSF, or ConsumerLab). A common starting point in trials was around 100 mg/day, taken with a meal containing some fat. If there is no improvement after roughly eight weeks, discuss with your clinician whether a dose increase or a different approach makes more sense.

Step 4: Recheck LDL After Starting

CoQ10 is not expected to significantly change LDL-cholesterol, but confirming that rosuvastatin is still hitting its LDL target after adding any new supplement is reasonable clinical hygiene, not a specific concern about this combination.